
CLAIMS

WHAT IS CLAIMED IS:


1. A compound of Formula V–A2:



Formula V–A2

or a pharmaceutically acceptable salt thereof,

B is a moiety of Formula II:



;

Formula II

wherein W_c is C_6-C_{10} aryl, 5-18 membered-heteroaryl or C_3-C_{10} cycloalkyl;

q is an integer of 0 or 1;

R^1 is hydrogen, C_1-C_{10} alkyl, or halo;

R^2 is C_1-C_{10} alkyl or halo;

R^3 is halo; and

each instance of R^9 is independently hydrogen, C_1-C_{10} alkyl, or 3-18 membered- heterocycloalkyl.


2. The compound of claim 1, wherein R^3 is –F.

~~3. The compound of claim 1, wherein R^3 is –Cl.~~

4. The compound of any of claims 1 to 3, wherein R^9 is methyl or ethyl.


5. The compound of any of claims 1 to 4, wherein W_c is phenyl or cyclopropyl, which is optionally substituted by at least one of $–CH_3$, $–CH_2CH_3$, $–CF_3$, –Cl or –F.

6. The compound of any of claims 1 to 5 having the formula:




7. The compound of claim 6, wherein R^2 is H.


8. The compound of any of claims 1 to 5 having the formula:




9. The compound of any of claims 1 to 5 having the formula:



~~10. The compound of any of claims 1 to 5 having the formula:~~




11. A compound having the following formula:




or a pharmaceutically acceptable salt thereof.

~~12. The compound of any of claims 1 to 10, wherein the compound is the S-enantiomer~~ having an enantiomeric purity selected from greater than 55%, greater than 80%, greater than 90%, and greater than 95%.



13. A compound selected from:








and


.


14. A compound having a formula selected from the group consisting of:



,

,






,



,




, and

or a pharmaceutically acceptable salt thereof.

15. A compound having the following formula:



or a pharmaceutically acceptable salt thereof.

16. A pharmaceutical composition comprising a compound, or a pharmaceutically acceptable salt thereof, of any of claims 1-15 and a pharmaceutically acceptable excipient.

17. The compound, the pharmaceutically acceptable salt thereof, or the pharmaceutical composition, of any of claims 1-16 for use in the treatment of a disorder in a subject , wherein said disorder is chosen from one or more of cancer, bone disorder, inflammatory disease, immune disease, nervous system disease, metabolic disease, respiratory disease, thrombosis, or cardiac disease.

18. Use of a compound, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition, of any of claims 1-16, for the manufacture of a medicament for treating a disorder in a subject , wherein said disorder is chosen from one or more of cancer, bone disorder, inflammatory disease, immune disease, nervous system disease, metabolic disease, respiratory disease, thrombosis, or cardiac disease.

19. Use of a compound, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition, of any of claims 1-16 for the manufacture of a medicament for treating one or more of an inflammatory disease, autoimmune disease, a respiratory disease, asthma, emphysema, allergy, dermatitis, rheumatoid arthritis, osteoarthritis, inflammatory bowel diseases, chronic obstructive pulmonary disorder, psoriasis, multiple sclerosis, disorders related to diabetic complications, psoriasis, lupus erythematosus, scleroderma, or graft versus host disease in a subject.

20. The use according to any of claims 18 or 19, wherein the inflammatory or immune disease is chosen from one or more of:

(i) bursitis, lupus, acute disseminated encephalomyelitis (ADEM), Addison's disease, antiphospholipid antibody syndrome (APS), aplastic anemia, autoimmune

~~hepatitis, coeliac disease, crohn's disease, diabetes mellitus (type 1), Goodpasture's~~ syndrome, Graves' disease, Guillain-Barré syndrome (GBS), Hashimoto's disease, inflammatory bowel disease, lupus erythematosus, myasthenia gravis, opsoclonus myoclonus syndrome (OMS), optic neuritis, Ord's thyroiditis,ostheoarthritis, uveoretinitis,

pemphigus, polyarthritis, primary biliary cirrhosis, Reiter's syndrome, Takayasu's arteritis, temporal arteritis, warm autoimmune hemolytic anemia, Wegener's granulomatosis, alopecia universalis, Chagas' disease, chronic fatigue syndrome, dysautonomia, endometriosis, hidradenitis suppurativa, interstitial cystitis, neuromyotonia, sarcoidosis, scleroderma, ulcerative colitis, vitiligo, vulvodynia, appendicitis, arteritis, arthritis, blepharitis, bronchiolitis, bronchitis, cervicitis, cholangitis, cholecystitis, chorioamnionitis, colitis, conjunctivitis, cystitis, dacryoadenitis, dermatomyositis, endocarditis, endometritis, enteritis, enterocolitis, epicondylitis, epididymitis, fasciitis, fibrositis, gastritis, gastroenteritis, gingivitis, hepatitis, hidradenitis, ileitis, iritis, laryngitis, mastitis, meningitis, myelitis, myocarditis, myositis, nephritis, omphalitis, oophoritis, orchitis, osteitis, otitis, pancreatitis, parotitis, pericarditis, peritonitis, pharyngitis, pleuritis, phlebitis, pneumonitis, proctitis, prostatitis, pyelonephritis, rhinitis, salpingitis, sinusitis, stomatitis, synovitis, tendonitis, tonsillitis, uveitis, vaginitis, vasculitis, or vulvitis;

(ii) perennial allergic rhinitis, mesenteritis, acrodermatitis, angiodermatitis, atopic dermatitis, contact dermatitis, eczema, erythema multiforme, intertrigo, Stevens Johnson syndrome, toxic epidermal necrolysis, skin allergy, severe allergic reaction/anaphylaxis, allergic granulomatosis, allergic conjunctivitis , chorioretinitis, infectious keratoconjunctivitis, keratoconjunctivitis, ophthalmia neonatorum, trachoma, ocular inflammation, blepharoconjunctivitis, pericoronitis, rhinopharyngitis, sialadenitis, musculoskeletal system inflammation, adult onset Stills disease, Behcets disease, chondrocalcinosis, dactylitis, Felty syndrome, gout, infectious arthritis, Lyme disease, inflammatory osteoarthritis, periarthritis, Ross River virus infection, acute respiratory distress syndrome, acute bronchitis, acute sinusitis, allergic rhinitis, asthma, severe refractory asthma, pleurisy, seasonal allergic rhinitis, status asthmaticus, tracheobronchitis, serositis, neuromyelitis optica, poliovirus infection, Alport syndrome, balanitis, epididymo orchitis, focal segmental, glomerulosclerosis,

~~glomerulonephritis, IgA nephropathy (Berger's Disease)~~, parametritis, pelvic inflammatory disease, pyelitis, pyelocystitis, hyperuricemia arteritis, chylopericarditis, Dressler syndrome, endarteritis, extracranial temporal

arteritis, HIV associated arteritis, intracranial temporal arteritis, Kawasaki disease, lymphangiophlebitis, Mondor disease, or periarteritis; or

(iii) jejunitis, mucositis, non alcoholic steatohepatitis, non viral hepatitis, autoimmune pancreatitis, perihepatitis, pouchitis, pseudomembranous colitis, rectosigmoiditis, salpingoperitonitis, sigmoiditis, steatohepatitis, Churg Strauss syndrome, ulcerative proctitis, irritable bowel syndrome, gastrointestinal inflammation, acute enterocolitis, anusitis, Balser necrosis, Crohns disease, diverticulitis, enterohepatitis, eosinophilic esophagitis, esophagitis, hemorrhagic enteritis, hepatitis virus infection, hepatocholangitis, hypertrophic gastritis, ileocecitis, ankylosing spondylitis, rheumatoid arthritis, juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, lupus (cutaneous/systemic/ nephritis), AIDS, agammaglobulinemia, AIDS related complex, Brutons disease, Chediak Higashi syndrome, common variable immunodeficiency, DiGeorge syndrome, dysgammaglobulinemia, immunoglobulindeficiency, Job syndrome, Nezelof syndrome, phagocyte bactericidal disorder, Wiskott Aldrich syndrome, asplenia, elephantiasis, hypersplenism, lymphadenopathy, lymphedema, lymphocele, Nonne Milroy Meige syndrome, spleen disease, splenomegaly, thymoma, thymus disease, perivasculitis, pleuropericarditis, polyarteritis nodosa, Takayasus arteritis, thromboangiitis, thromboangiitis obliterans, thromboendocarditis, thrombophlebitis, or COPD.

21. The use according to claim 18 or 19, wherein the compound is to be administered in an amount effective to ameliorate one or more symptoms associated with rheumatoid arthritis chosen from one or more of a reduction in the swelling of the joints, a reduction in serum anti-collagen levels, a reduction in bone resorption, a reduction in cartilage damage, a reduction in pannus, and a reduction in inflammation

22. Use of a compound, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition, of any of claims 1 to 16 for the manufacture of a medicament for treating or preventing a cancer in a subject.

~~23. The use according to claim 22, wherein the cancer is chosen from acute myelogenous leukemia,~~ thymus, brain, lung, squamous cell, skin, eye, retinoblastoma, intraocular melanoma, oral cavity and oropharyngeal, bladder, gastric, stomach, pancreatic, bladder, breast, cervical, head, neck, renal, kidney, liver, ovarian, prostate, colorectal, esophageal, testicular, gynecological, thyroid, CNS, PNS, AIDS-related (*e.g.* Lymphoma and Kaposi's Sarcoma) or viral-induced cancer.

24. Use of a compound, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition, of any of claims 1-16 for the manufacture of a medicament for treating a respiratory disease in a subject.

25. The use of claim 22, wherein the cancer is leukemia or lymphoma.

26. The use of claim 24, wherein the respiratory disease is asthma, chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, or bronchiectasis.

27. The use according to any of claims 18-26, wherein a second therapeutic is to be administered to the subject.

28. The use of claim 27, wherein the disorder is an inflammatory, autoimmune or immune disease and the second therapeutic is chosen from:
(i) non-steroidal anti-inflammatory drugs (NSAIDs), acetylsalicylic acid, ibuprofen; naproxen, indomethacin, nabumetone, tolmetin, corticosteroids, Prednisone,

~~Chloroquine (Aralen), hydroxychloroquine (Plaquenil), Azathioprine (Imuran), cyclophosphamide~~ (Cytoxan), methotrexate, cyclosporin, rapamycin, rapamycin analogs, TORC1 inhibitors, TORC2 inhibitors, or agents that inhibit IgE activity include, for example, anti-IgE antibodies;

(ii) Enbrel®, Remicade®, Humira®, Avonex®, and Rebif® for the treatment of autoimmune disease; or

(iii) Xolair®, Advair®, Singulair®, and Spiriva® for the treatment of respiratory disease.

29. The use of claim 27, wherein the disorder is cancer and the second therapeutic is chosen from one or more of a chemotherapeutic agent, a cytotoxic agent, radiation, and a non-peptide small molecules.

30. The use of claim 27, wherein the second therapeutic is chosen from one or more of:

(i) thiotepa, cyclosphosphamide, busulfan, improsulfan, piposulfan, benzodopa, carboquone, meturedopa, uredopa, altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphaoramide, trimethylolomelamine, chlorambucil, chlornaphazine, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard, carmustine, chlorozotocin, fotemustine, lomustine, nimustine, ranimustine, aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, calicheamicin, carabicin, carminomycin, carzinophilin, Casodex™ , chromomycins, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin, epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonig carboplatin rin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin, methotrexate, 5-fluorouracil (5-FU), denopterin, pteropterin, trimetrexate, fludarabine, 6-mercaptopurine, thiamiprine, thioguanine, ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone, aminoglutethimide, mitotane, trilostane, frolinic acid, aceglatone, aldophosphamide glycoside, aminolevulinic acid, amsacrine, bestrabucil, bisantrene, edatraxate, defofamine, demecolcine, diaziquone, elfomithine, elliptinium acetate, etoglucid, gallium nitrate, hydroxyurea, lentinan, lonidamine, mitoguazone,

~~mitoxantrone, mopidamol, nitracrine, pentostatin, phenamet, pirarubicin, podophyllinic~~ acid, 2-ethylhydrazide, procarbazine, PSK [RTM.], razoxane, sizofiran, spirogermanium, tenuazonic acid, triaziquone, 2,2',2''-trichlorotriethylamine, urethan, vindesine, dacarbazine, mannomustine, mitobronitol, mitolactol, pipobroman, gacytosine, arabinoside, paclitaxel, docetaxel, retinoic acid, esperamicins, or capecitabine;

(ii) tamoxifen, raloxifene, 4-hydroxytamoxifen, trioxifene, keoxifene, LY 117018, onapristone, toremifene, flutamide, nilutamide, bicalutamide, leuprolide, goserelin, gemcitabine, 6-thioguanine, mercaptopurine, cisplatin, carboplatin, vinblastine, platinum, etoposide (VP-16), mitomycin C, vincristine, vinorelbine, navelbine, novantrone, teniposide, daunomycin, aminopterin, xeloda, ibandronate, camptothecin-11 (CPT-11), topoisomerase inhibitor RFS 2000, or difluoromethylornithine (DMFO);

(iii) Herceptin®, Avastin®, Erbitux®, Rituxan®, Taxol®, Arimidex®, Taxotere®, and Velcade®; or

(iv) a non-peptide small molecule chosen from imatinib mesylate, bortezomib, gefitinib, or adriamycin.

~~31. Use of a compound of claim 11 or 15, a pharmaceutically acceptable salt thereof or a~~ composition comprising a compound of claim 11 or 15 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for use in the treatment of a disorder chosen from one or more of cancer, bone disorder, inflammatory disease, immune disease, nervous system disease, metabolic disease, respiratory disease, thrombosis, or cardiac disease.

~~32. The use of claim 31, wherein the cancer is selected from acute myelogenous leukemia (AML),~~ chronic myelogenous leukemia (CML), myelodysplastic syndrome (MDS), myeloproliferative disorders, mastocytosis, mast cell disorder, thrombosis, Hodgkin disease, non-Hodgkin lymphomas, diffuse large B-cell lymphoma, adult T-cell lymphoma, acute lymphocytic leukemia (ALL), T-cell acute lymphocytic leukemia, chronic lymphocytic leukemia, and multiple myeloma (MM).

33. The use of claim 31, wherein the cancer is a leukemia or a lymphoma.

34. The use of claim 33, wherein the leukemia is selected from acute lymphocytic leukemia, chronic lymphocytic leukemia, hairy cell leukemia, myelodysplasia, myeloproliferative disorders, acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), multiple myeloma (MM), myelodysplastic syndrome (MDS), and mastocytosis.


35. The use of claim 33, wherein the lymphoma is selected from diffuse large B-cell lymphoma, B-cell immunoblastic lymphoma, small non-cleaved cell lymphoma, human lymphotropic virus-type 1 (HTLV-1) leukemia/lymphoma, adult T-cell lymphoma, mantle cell lymphoma, Hodgkin disease, and non-Hodgkin lymphomas.

36. The use of claim 31, wherein the inflammatory disease or immune disease is rheumatoid arthritis.


37. The use of claim 36, wherein the amount of the compound is effective to ameliorate one or more symptoms associated with rheumatoid arthritis selected from one or more of a reduction in the swelling of the joints, a reduction in serum anti-collagen levels, a reduction in bone resorption, a reduction in cartilage damage, a reduction in pannus, or a reduction in inflammation.

38. The use of claim 31, wherein the respiratory disease is chosen from asthma, chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, or bronchiectasis.

~~39. The use of claim 31, wherein the respiratory disease is asthma.~~




~~40. Use of a compound having the following formula:~~




or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating chronic lymphocytic leukemia.

41. Use of a compound having the following formula:




or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating non-Hodgkin lymphoma.

42. Use of a compound having the following formula:



or a phramceutically acceptable salt thereof, for the manufacture of a medicament for treating chronic lymphocytic leukemia.

43. Use of a compound having the following formula:



or a phramceutically acceptable salt thereof, for the manufacture of a medicament for treating non-Hodgkin lymphoma.

44. The use of claim 33, wherein the cancer is a leukemia, wherein the leukemia is chronic lymphocytic leukemia.

45. The use of claim 33, wherein the cancer is lymphoma, wherein the lymphoma is non-Hodgkin lymphoma.


46. The use of claim 25, wherein:

(i) the leukemia is chosen from acute lymphocytic leukemia, T-cell acute lymphocytic leukemia, chronic lymphocytic leukemia, hairy cell leukemia, myelodysplasia, myeloproliferative disorders, acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), mastocytosis, chronic lymphocytic leukemia (CLL), multiple myeloma (MM), myelodysplastic syndrome (MDS), or mastocytosis; or

(ii) the lymphoma is chosen from diffuse large B-cell lymphoma, B-cell immunoblastic lymphoma, small non-cleaved cell lymphoma, human lymphotropic virus-type 1 (HTLV-1) leukemia/lymphoma, adult T-cell lymphoma, mantle cell lymphoma (MCL), Hodgkin disease, or non-Hodgkin lymphomas.

CLAIMS


1. A compound of Formula V–A:



Formula V–A

or a pharmaceutically acceptable salt thereof,

B is a moiety of Formula II:



;

Formula II

wherein W_c is C_6-C_{10} aryl, 5-18 membered-heteroaryl or C_3-C_{10} cycloalkyl;

q is an integer of 0 or 1;


R^1 is hydrogen, C_1-C_{10} alkyl, or halo;

R^2 is C_1-C_{10} alkyl or halo;

R^3 is halo; and

R^9 is hydrogen, C_1-C_{10} alkyl, or 3-18 membered- heterocycloalkyl.

2. The compound of claim 1 having Formula V-A2:



Formula V-A2

or a pharmaceutically acceptable salt thereof.


3. The compound of claim 1 or 2, wherein R^3 is –F.

4. The compound of claim 1 or 2, wherein R^3 is –Cl.

5. The compound of any of claims 1 to 4, wherein R^9 is methyl or ethyl.


6. The compound of any of claims 1 to 5, wherein W_c is phenyl or cyclopropyl, which is optionally substituted by at least one of $–CH_3$, $–CH_2CH_3$, $–CF_3$, –Cl or –F.

7. The compound of any of claims 1 to 6 having the formula:




8. The compound of claim 7, wherein R^2 is H.


9. The compound of any of claims 1 to 6 having the formula:




10. The compound of any of claims 1 to 6 having the formula:



11. The compound of any of claims 1 to 6 having the formula:



12. A compound having the following formula:




,


or a pharmaceutically acceptable salt thereof.

13. The compound of any of claims 1 to 12, wherein the compound is the S-enantiomer having an enantiomeric purity selected from greater than 55%, greater than 80%, greater than 90%, and greater than 95%.

14. A compound having a formula selected from the group consisting of:




and




.


15. A compound having a formula selected from the group consisting of:











,



,




,


,

,

,

,

,

,

, and


or a pharmaceutically acceptable salt thereof.

16. A compound having the following formula:



or a pharmaceutically acceptable salt thereof.

17. A pharmaceutical composition comprising a compound, or a pharmaceutically acceptable salt thereof, of any of claims 1-16 and a pharmaceutically acceptable excipient.

18. Use of a compound, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition, of any of claims 1-17, for the manufacture of a medicament for treating a disorder in a subject, wherein the disorder is cancer, and wherein the cancer is selected from leukemia or lymphoma.

19. Use of a compound, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition, of any of claims 1-17, for the manufacture of a medicament for treating a disorder in a subject, wherein the disorder is cancer, and wherein the cancer is selected from thymus, brain, lung, squamous cell, skin, eye, retinoblastoma, intraocular melanoma, oral cavity and oropharyngeal, bladder, gastric, stomach, pancreatic, bladder, breast, cervical, head, neck, renal, kidney, liver, ovarian, prostate, colorectal, esophageal, testicular, gynecological, thyroid, CNS, PNS, AIDS-related cancer, Kaposi's Sarcoma, or viral-induced cancer.

20. Use of a compound, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition, of any of claims 1-17, for the manufacture of a medicament for treating a disorder in a subject, wherein said disorder is selected from one or more of

an inflammatory disease, immune disease, respiratory disease, thrombosis, or cardiovascular disease;

wherein the inflammatory disease or immune disease is selected from (i) bursitis, lupus, acute disseminated encephalomyelitis (ADEM), Addison's disease, antiphospholipid antibody syndrome (APS), aplastic anemia, autoimmune hepatitis, coeliac disease, Crohn's disease, diabetes mellitus (type 1), Goodpasture's syndrome, Graves' disease, Guillain-Barré syndrome (GBS), Hashimoto's disease, inflammatory bowel disease, lupus erythematosus, myasthenia gravis, opsoclonus myoclonus syndrome (OMS), optic neuritis, Ord's thyroiditis, ostheoarthritis, uveoretinitis, pemphigus, polyarthritis, primary biliary cirrhosis, Reiter's syndrome, Takayasu's arteritis, temporal arteritis, warm autoimmune hemolytic anemia, Wegener's granulomatosis, alopecia universalis, Chagas' disease, chronic fatigue syndrome, dysautonomia, endometriosis, hidradenitis suppurativa, interstitial cystitis, neuromyotonia, sarcoidosis, scleroderma, ulcerative colitis, vitiligo, vulvodynia, appendicitis, arteritis, arthritis, blepharitis, bronchiolitis, bronchitis, cervicitis, cholangitis, cholecystitis, chorioamnionitis, colitis, conjunctivitis, cystitis, dacryoadenitis, dermatomyositis, endocarditis, endometritis, enteritis, enterocolitis, epicondylitis, epididymitis, fasciitis, fibrositis, gastritis, gastroenteritis, gingivitis, hepatitis, hidradenitis, ileitis, iritis, laryngitis, mastitis, meningitis, myelitis, myocarditis, myositis, nephritis, omphalitis, oophoritis, orchitis, osteitis, otitis, pancreatitis, parotitis, pericarditis, peritonitis, pharyngitis, pleuritis, phlebitis, pneumonitis, proctitis, prostatitis, pyelonephritis, rhinitis, salpingitis, sinusitis, stomatitis, synovitis, tendonitis, tonsillitis, uveitis, vaginitis, vasculitis, or vulvitis;

(ii) perennial allergic rhinitis, mesenteritis, acrodermatitis, angiodermatitis, atopic dermatitis, contact dermatitis, eczema, erythema multiforme, intertrigo, Stevens Johnson syndrome, toxic epidermal necrolysis, skin allergy, severe allergic reaction/anaphylaxis, allergic granulomatosis, allergic conjunctivitis, chorioretinitis, infectious keratoconjunctivitis, keratoconjunctivitis, ophthalmia neonatorum, trachoma, ocular inflammation, blepharoconjunctivitis, pericoronitis, rhinopharyngitis, sialadenitis, musculoskeletal system inflammation, adult onset Stills disease, Behcets disease, chondrocalcinosis, dactylitis, Felty syndrome, gout, infectious arthritis, Lyme disease,

inflammatory osteoarthritis, periarthritis, Ross River virus infection, acute respiratory distress syndrome, acute bronchitis, acute sinusitis, allergic rhinitis, asthma, severe refractory asthma, pleurisy, seasonal allergic rhinitis, status asthmaticus, tracheobronchitis, serositis, neuromyelitis optica, poliovirus infection, Alport syndrome, balanitis, epididymo orchitis, focal segmental, glomerulosclerosis, glomerulonephritis, IgA nephropathy (Berger's Disease), orchitis, parametritis, pelvic inflammatory disease, pyelitis, pyelocystitis, hyperuricemia, aortitis, chylopericarditis, Dressler syndrome, endarteritis, extracranial temporal arteritis, HIV associated arteritis, intracranial temporal arteritis, Kawasaki disease, lymphangiophlebitis, Mondor disease, or periarteritis; and

(iii) jejunitis, mucositis, non alcoholic steatohepatitis, non viral hepatitis, autoimmune pancreatitis, perihepatitis, pouchitis, pseudomembranous colitis, rectosigmoiditis, salpingoperitonitis, sigmoiditis, steatohepatitis, Churg Strauss syndrome, ulcerative proctitis, irritable bowel syndrome, gastrointestinal inflammation, acute enterocolitis, anusitis, Balser necrosis, diverticulitis, enterohepatitis, eosinophilic esophagitis, esophagitis, hemorrhagic enteritis, hepatitis virus infection, hepatocholangitis, hypertrophic gastritis, ileocecitis, ankylosing spondylitis, rheumatoid arthritis, juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, lupus (cutaneous/systemic/nephritis), AIDS, agammaglobulinemia, AIDS related complex, Brutons disease, Chediak Higashi syndrome, common variable immunodeficiency, DiGeorge syndrome, dysgammaglobulinemia, immunoglobulindeficiency, Job syndrome, Nezelof syndrome, phagocyte bactericidal disorder, Wiskott Aldrich syndrome, asplenia, elephantiasis, hypersplenism, lymphadenopathy, lymphedema, lymphocele, Nonne Milroy Meige syndrome, spleen disease, splenomegaly, thymoma, thymus disease, perivasculitis, pleuropericarditis, polyarteritis nodosa, thromboangiitis, thromboangiitis obliterans, thromboendocarditis, thrombophlebitis, or COPD;

wherein the respiratory disease is selected from asthma, chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, or bronchiectasis; and

wherein the cardiovascular disease is selected from atherosclerosis, restenosis, vascular occlusion, carotid obstructive disease, or acute coronary syndrome.

21. Use of a compound, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition, of any of claims 1-17 for the manufacture of a medicament for treating one or more of asthma, emphysema, allergy, dermatitis, rheumatoid arthritis, osteoarthritis, inflammatory bowel diseases, chronic obstructive pulmonary disorder, psoriasis, multiple sclerosis, disorders related to diabetic complications, psoriasis, lupus erythematosus, scleroderma, or graft versus host disease in a subject.

22. Use of a compound, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition, of any of claims 1-17 for the manufacture of a medicament for ameliorating one or more symptoms associated with rheumatoid arthritis selected from one or more of a reduction in the swelling of the joints, a reduction in serum anti-collagen levels, a reduction in bone resorption, a reduction in cartilage damage, a reduction in pannus, or a reduction in inflammation.

23. The use of claim 18, wherein:
(i) the leukemia is selected from acute myelogenous leukemia (AML), acute lymphocytic leukemia, adult T-cell leukemia, chronic lymphocytic leukemia (CLL), hairy cell leukemia, myelodysplasia, myeloproliferative disorders, chronic myelogenous leukemia (CML), multiple myeloma (MM), myelodysplastic syndrome (MDS), human lymphotropic virus-type 1 (HTLV-1) leukemia, mastocytosis, or B-cell acute lymphoblastic leukemia; or
(ii) the lymphoma is selected from diffuse large B-cell lymphoma, B-cell immunoblastic lymphoma, small non-cleaved cell lymphoma, human lymphotropic virus-type 1 (HTLV-1) leukemia/lymphoma, adult T-cell lymphoma, mantle cell lymphoma (MCL), Hodgkin disease, non-Hodgkin lymphomas, AIDS-related lymphoma, peripheral T-cell lymphoma, cutaneous T-cell lymphoma, multiple myeloma, or follicular lymphoma.

24. Use of a compound, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition, of any of claims 1-17 for the manufacture of a medicament for treating a respiratory disease in a subject, wherein the respiratory disease is asthma,

chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, or bronchiectasis.

25. The use according to any of claims 18-24, wherein the medicament further comprises one or more second therapeutic agent.

26. The use of claim 25, wherein the second therapeutic agent is a chemotherapeutic agent.

27. The use of claim 26, wherein the chemotherapeutic agent is selected from mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, anti-hormones, angiogenesis inhibitors, anti-androgens, alkylating agents, alkyl sulfonates, aziridines, ethylenimines, methylamelamines, nitrogen mustards, nitrosureas, anti-metabolites, folic acid analogues, purine analogues, folic acid replenishers, taxanes, anti-hormonal agents that act to regulate or inhibit hormone action on tumors, anti-estrogens, anti-androgens, LHRH agonists, photodynamic therapies, nitrosureas, alkylsulfonates, triazenes, platinum containing compounds, vinca alkaloids, taxoids, epipodophyllins, DHFR inhibitors, IMP dehydrogenase inhibitors, ribonucleotide reductase inhibitors, uracil analogues, cytocine analogues, purine analogues, Vitamin D analogues, isoprenylation inhibitors, dopaminergic neurotoxins, cell cycle inhibitors, MDR inhibitors, Ca^{2+} ATPase inhibitors, tyrosine kinase inhibitors, proteasome inhibitors, or mTOR inhibitors.

28. The use of claim 26, wherein the chemotherapeutic agent is selected from imatinib, bortezomib, bicalutamide, adriamycin, thiotepa, cyclophosphamide, busulfan, improsulfan, piposulfan, benzodopa, carboquone, meturedopa, uredopa, altretamine, triethylenemelamine, trietylenephosphoramide, triethylenethiophosphaoramide trimethylolomelamine, chlorambucil, chlornaphazine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard, chlorozotocin, fotemustine, nimustine,

ranimustine, antibiotics such as aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, calicheamicin, carabicin, carminomycin, carzinophilin, chromomycins, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, esorubicin, idarubicin, marcellomycin, mitomycins, mycophenolic acid, nogalamycin, olivomycins, peplomycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin, 5-fluorouracil (5-FU), pteropterin, trimetrexate, denopterin, methotrexate, pteropterin, trimetrexate, ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone, aminoglutethimide, mitotane, trilostane, frolinic acid, aceglatone, aldophosphamide, glycoside, aminolevulinic acid, amsacrine, bestrabucil, bisantrene, edatraxate, defofamine, demecolcine, diaziquone, elfomithine, elliptinium acetate, etoglucid, gallium nitrate, lentinan, lonidamine, mitoguazone, mitoxantrone, mopidamol, nitracrine, pentostatin, phenamet, pirarubicin, podophyllinic acid, 2-ethylhydrazide, procarbazine, polysaccharide K, razoxane, sizofiran, spirogermanium, tenuazonic acid, triaziquone, 2,2',2"-trichlorotriethylamine, urethane, mannomustine, mitobronitol, mitolactol, pipobroman, gacytosine, arabinoside ("Ara-C"), paclitaxel, docetaxel, retinoic acid, esperamicins, raloxifene, 4-hydroxytamoxifen, trioxifene, keoxifene, LY 117018, onapristone, toremifene, flutamide, nilutamide, leuprolide, goserelin, 6-thioguanine, mercaptopurine, cisplatin, carboplatin, vinblastine, platinum, mitomycin C, vincristine, vinorelbine, navelbine, novantrone, teniposide, daunomycin, aminopterin, xeloda, ibandronate, camptothecin-11 (CPT-11), topoisomerase inhibitor RFS 2000, difluoromethylornithine (DMFO), tamoxifen, megestrol, leuprolide, flutamide, vertoporfin(BPD-MA), phthalocyanine, photosensitizer Pc4, demethoxy-hypocrellin A (2BA-2-DMHA), estramustine, carmustine (BCNU), lomustine (CCNU), treosulfan, dacarbazine, temozolomide, oxaliplatin, vindesine, DHA-paclitaxel, Taxoprexin, PG-paclitaxel, paclitaxel poliglumex, CT-2103, xyotax, ANG1005, paclitaxel-EC-1, glucose-conjugated paclitaxel, etoposide, etoposide phosphate, topotecan, 9-aminocamptothecin, camptoirinotecan, irinotecan, crisnatol, mytomycin C, dichloromethotrexate, edatrexate, tiazofurin, ribavirin, EICAR, hydroxyurea, deferoxamine, 5-fluorouracil (5-FU),

ratitrexed, tegafur-uracil, capecitabine, cytosine arabinoside, fludarabine, mercaptopurine thioguanine, EB 1089, CB 1093, KH 1060, lovastatin, 1-methyl-4-phenylpyridinium ion, staurosporine, actinomycin D, dactinomycin, bleomycin A2, bleomycin B2, peplomycin, doxorubicin, pegylated liposomal doxorubicin, epirubicin, pirarubicin, verapamil, thapsigargin, thalidomide, lenalidomide, axitinib (AG013736), bosutinib (SKI-606), cediranib (AZD2171), dasatinib (BMS-354825), erlotinib, gefitinib, lapatinib, lestaurtinib (CEP-701), neratinib (HKI-272), nilotinib, semaxanib, sunitinib SU11248, toceranib, vandetanib (ZD6474), vatalanib (PTK787, PTK/ZK), trastuzumab, bevacizumab, rituximab, cetuximab, panitumumab, ranibizumab, sorafenib, everolimus, alemtuzumab, gemtuzumab, ozogamicin, temsirolimus, ENMD-2076, PCI-32765, AC220, dovitinib lactate (TKI258, CHIR-258), BIBW 2992, SGX523, PF-04217903, PF-02341066, PF-299804, BMS-777607, ABT-869, MP470, BIBF 1120, AP24534, JNJ-26483327, MGCD265, DCC-2036, BMS-690154, CEP-11981, tivozanib (AV-951), OSI-930, MM-121, XL-184, XL-647, XL228, rapamycin, ridaforolimus, AP23573, AZD8055, BEZ235, BGT226, XL765, PF-4691502, GDC0980, SF1126, OSI-027, oblimersen, gemcitabine, leucovorin, pemetrexed, prednisolone, dexamethasone, campathecin, plicamycin, asparaginase, methopterin, porfiromycin, leurosidine, leurosine, trabectedin, procarbazine, discodermolide, or hexamethyl melamine, or a pharmaceutically acceptable salt thereof.

29. The use of claim 25, wherein the second therapeutic agent is selected from
(i) an agent that inhibits IgE production or activity,
(ii) an anti-inflammatory drug,
(iii) anticoagulants,
(iv) a biotherapeutic agent,
(v) a bronchodilator,
(vi) an anti-angiogenesis agents,
(vii) a diuretic agent,
(viii) a hormone or therapeutic peptide or protein,
(ix) radiation therapy, or

(x) a therapeutic antibody.

30. The use of claim 29, wherein

(i) the agent that inhibits IgE production or activity is selected from TEI-9874, 2-(4-(6-cyclohexyloxy-2-naphtyloxy)phenylacetamide)benzoic acid, rapamycin, rapamycin analogs, TORC1 inhibitors, TORC2 inhibitors, anti-IgE antibodies, omalizumab, or TNX-901; or

(ii) the non-steroidal anti-inflammatory drug is selected from acetylsalicylic acid, ibuprofen, naproxen, indomethacin, nabumetone, tolmetin, a corticosteroid, prednisone, chloroquine, or hydroxychloroquine; or

(iii) the anticoagulant is selected from aspirin, heparin, or coumadin; or

(iv) the biotherapeutic agent is selected from tumor necrosis factor, interferon α, interferon γ, IL-1, IL-2, IL-4, IL-6, IL-12, GM-CSF, Herceptin (trastuzumab), T-DM1, bevacizumab, cetuximab, panitumumab, rituximab, or tositumomab; or

(v) the bronchodilator is selected from ephedrine, adrenaline, fenoterol, formoterol, isoprenaline, metaproterenol, phenylephrine, phenylpropanolamine, pirbuterol, reproterol, rimiterol, salbutamol, salmeterol, terbutalin, isoetharine, tulobuterol, orciprenaline or (-)-4-amino-3,5-dichloro-α-[[[6-[2-(2-pyridinyl)ethoxy]hexyl]-amino]methyl]benzenemethanol; or

(vi) the anti-angiogenic agent is selected from MMP-2 (matrix-metalloprotienase 2) inhibitors, MMP-9 (matrix-metalloproteinase 9) inhibitors, or COX-II (cyclooxygenase II) inhibitors; or

(vii) the diuretic agent is selected from amiloride, anticholinergics, ipratropium, atropine or oxitropium; or

(viii) the hormone or therapeutic peptide or protein is selected from cortisone, hydrocortisone, prednisolone, xanthines, aminophylline, choline theophyllinate, lysine theophyllinate, theophylline, insulin or glucagon; or

(ix) the radiation therapy is selected from external-beam therapy, internal radiation therapy, implant radiation, stereotactic radiosurgery, systemic radiation therapy, radiotherapy or permanent or temporary interstitial brachytherapy.

31. The use of claim 25, wherein the second therapeutic agent is a therapeutic antibody selected from cetuximab, panitumumab, trastuzumab, rituximab, tositumomab, alemtuzumab, bevacizumab, gemtuzumab, an anti-CD20 antibody or an anti-receptor tyrosine kinase antibody.

32. The use of claim 31, wherein the second therapeutic agent is an anti-CD20 antibody.

33. The use of claim 32, wherein the anti-CD20 antibody is rituximab.

34. The use of claim 26, wherein the chemotherapeutic agent is a nitrogen mustard.

35. The use of claim 26, wherein the chemotherapeutic agent is chlorambucil.

36. Use of a compound of claim 12 or 16, a pharmaceutically acceptable salt thereof or a composition comprising a compound of claim 12 or 16 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of a disorder selected from cancer, bone disorder, wherein the cancer is selected from leukemia or lymphoma.

37. Use of a compound of claim 12 or 16, a pharmaceutically acceptable salt thereof or a composition comprising a compound of claim 12 or 16 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of a disorder selected from cancer, bone disorder, wherein the cancer is selected from thymus, brain, lung, squamous cell, skin, eye, retinoblastoma, intraocular melanoma, oral cavity and oropharyngeal, bladder, gastric, stomach, pancreatic, bladder, breast, cervical, head, neck, renal, kidney, liver, ovarian, prostate, colorectal, esophageal, testicular, gynecological, thyroid, CNS, PNS, AIDS-related cancer, Kaposi's Sarcoma, or viral-induced cancer.

38. Use of a compound of claim 12 or 16, a pharmaceutically acceptable salt thereof or a composition comprising a compound of claim 12 or 16 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of a

disorder selected from one or more of bone disorder, inflammatory disease, immune disease, respiratory disease, thrombosis, or cardiovascular disease;

wherein the inflammatory disease or immune disease is selected from (i) bursitis, lupus, acute disseminated encephalomyelitis (ADEM), Addison's disease, antiphospholipid antibody syndrome (APS), aplastic anemia, autoimmune hepatitis, coeliac disease, Crohn's disease, diabetes mellitus (type 1), Goodpasture's syndrome, Graves' disease, Guillain-Barré syndrome (GBS), Hashimoto's disease, inflammatory bowel disease, lupus erythematosus, myasthenia gravis, opsoclonus myoclonus syndrome (OMS), optic neuritis, Ord's thyroiditis, ostheoarthritis, uveoretinitis, pemphigus, polyarthritis, primary biliary cirrhosis, Reiter's syndrome, Takayasu's arteritis, temporal arteritis, warm autoimmune hemolytic anemia, Wegener's granulomatosis, alopecia universalis, Chagas' disease, chronic fatigue syndrome, dysautonomia, endometriosis, hidradenitis suppurativa, interstitial cystitis, neuromyotonia, sarcoidosis, scleroderma, ulcerative colitis, vitiligo, vulvodynia, appendicitis, arteritis, arthritis, blepharitis, bronchiolitis, bronchitis, cervicitis, cholangitis, cholecystitis, chorioamnionitis, colitis, conjunctivitis, cystitis, dacryoadenitis, dermatomyositis, endocarditis, endometritis, enteritis, enterocolitis, epicondylitis, epididymitis, fasciitis, fibrositis, gastritis, gastroenteritis, gingivitis, hepatitis, hidradenitis, ileitis, iritis, laryngitis, mastitis, meningitis, myelitis, myocarditis, myositis, nephritis, omphalitis, oophoritis, orchitis, osteitis, otitis, pancreatitis, parotitis, pericarditis, peritonitis, pharyngitis, pleuritis, phlebitis, pneumonitis, proctitis, prostatitis, pyelonephritis, rhinitis, salpingitis, sinusitis, stomatitis, synovitis, tendonitis, tonsillitis, uveitis, vaginitis, vasculitis, or vulvitis;

(ii) perennial allergic rhinitis, mesenteritis, acrodermatitis, angiodermatitis, atopic dermatitis, contact dermatitis, eczema, erythema multiforme, intertrigo, Stevens Johnson syndrome, toxic epidermal necrolysis, skin allergy, severe allergic reaction/anaphylaxis, allergic granulomatosis, allergic conjunctivitis, chorioretinitis, infectious keratoconjunctivitis, keratoconjunctivitis, ophthalmia neonatorum, trachoma, ocular inflammation, blepharoconjunctivitis, pericoronitis, rhinopharyngitis, sialadenitis, musculoskeletal system inflammation, adult onset Stills disease, Behcets disease, chondrocalcinosis, dactylitis, Felty syndrome, gout, infectious arthritis, Lyme disease,

inflammatory osteoarthritis, periarthritis, Ross River virus infection, acute respiratory distress syndrome, acute bronchitis, acute sinusitis, allergic rhinitis, asthma, severe refractory asthma, pleurisy, seasonal allergic rhinitis, status asthmaticus, tracheobronchitis, serositis, neuromyelitis optica, poliovirus infection, Alport syndrome, balanitis, epididymo orchitis, focal segmental, glomerulosclerosis, glomerulonephritis, IgA nephropathy (Berger's Disease), orchitis, parametritis, pelvic inflammatory disease, pyelitis, pyelocystitis, hyperuricemia, aortitis, chylopericarditis, Dressler syndrome, endarteritis, extracranial temporal arteritis, HIV associated arteritis, intracranial temporal arteritis, Kawasaki disease, lymphangiophlebitis, Mondor disease, or periarteritis; and

(iii) jejunitis, mucositis, non alcoholic steatohepatitis, non viral hepatitis, autoimmune pancreatitis, perihepatitis, pouchitis, pseudomembranous colitis, rectosigmoiditis, salpingoperitonitis, sigmoiditis, steatohepatitis, Churg Strauss syndrome, ulcerative proctitis, irritable bowel syndrome, gastrointestinal inflammation, acute enterocolitis, anusitis, Balser necrosis, diverticulitis, enterohepatitis, eosinophilic esophagitis, esophagitis, hemorrhagic enteritis, hepatitis virus infection, hepatocholangitis, hypertrophic gastritis, ileocecitis, ankylosing spondylitis, rheumatoid arthritis, juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, lupus (cutaneous/systemic/nephritis), AIDS, agammaglobulinemia, AIDS related complex, Brutons disease, Chediak Higashi syndrome, common variable immunodeficiency, DiGeorge syndrome, dysgammaglobulinemia, immunoglobulindeficiency, Job syndrome, Nezelof syndrome, phagocyte bactericidal disorder, Wiskott Aldrich syndrome, asplenia, elephantiasis, hypersplenism, lymphadenopathy, lymphedema, lymphocele, Nonne Milroy Meige syndrome, spleen disease, splenomegaly, thymoma, thymus disease, perivasculitis, pleuropericarditis, polyarteritis nodosa, thromboangiitis, thromboangiitis obliterans, thromboendocarditis, thrombophlebitis, or COPD;

wherein the respiratory disease is selected from asthma, chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, or bronchiectasis; and

wherein the cardiovascular disease is selected from atherosclerosis, restenosis, vascular occlusion, carotid obstructive disease, or acute coronary syndrome.

39. The use of claim 36, wherein the leukemia is selected from acute myelogenous leukemia (AML), acute lymphocytic leukemia, adult T-cell leukemia, chronic lymphocytic leukemia (CLL), hairy cell leukemia, myelodysplasia, myeloproliferative disorders, chronic myelogenous leukemia (CML), multiple myeloma (MM), myelodysplastic syndrome (MDS), human lymphotropic virus-type 1 (HTLV 1) leukemia, mastocytosis, or B-cell acute lymphoblastic leukemia.


40. The use of claim 36, wherein the lymphoma is selected from diffuse large B-cell lymphoma, B-cell immunoblastic lymphoma, small non-cleaved cell lymphoma, human lymphotropic virus-type 1 (HTLV-1) leukemia/lymphoma, adult T-cell lymphoma, mantle cell lymphoma (MCL), Hodgkin disease, non-Hodgkin lymphomas, AIDS-related lymphoma, peripheral T-cell lymphoma, cutaneous T-cell lymphoma, multiple myeloma, or follicular lymphoma.


41. The use of claim 38, wherein the inflammatory disease or immune disease is rheumatoid arthritis.

42. Use of a compound, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition, of any of claims 1-17 for the manufacture of a medicament for ameliorating one or more symptoms associated with rheumatoid arthritis selected from one or more of a reduction in the swelling of the joints, a reduction in serum anti-collagen levels, a reduction in bone resorption, a reduction in cartilage damage, a reduction in pannus, or a reduction in inflammation.

43. The use of claim 38, wherein the respiratory disease is asthma.

44. Use of a compound having the following formula:




or


,

or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating cancer, wherein the cancer is selected from leukemia or lymphoma.

45. Use of a compound having the following formula:



,


or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating cancer, wherein the cancer is selected from leukemia or lymphoma.

46. The use of claim 44 or 45, wherein the leukemia is selected from acute myelogenous leukemia (AML), acute lymphocytic leukemia, adult T-cell leukemia, chronic lymphocytic leukemia (CLL), hairy cell leukemia, myelodysplasia, myeloproliferative disorders, chronic myelogenous leukemia (CML), multiple myeloma (MM), myelodysplastic syndrome (MDS), human lymphotropic virus-type 1 (HTLV 1) leukemia, mastocytosis, and B-cell acute lymphoblastic leukemia.

47. The use of claim 44 or 45, wherein the lymphoma is selected from diffuse large B-cell lymphoma, B-cell immunoblastic lymphoma, small non-cleaved cell lymphoma, human lymphotropic virus-type 1 (HTLV-1) leukemia/lymphoma, adult T-cell lymphoma, mantle cell lymphoma (MCL), Hodgkin disease, non-Hodgkin lymphomas,


AIDS-related lymphoma, peripheral T-cell lymphoma, cutaneous T-cell lymphoma, multiple myeloma, or follicular lymphoma.

48. Use of a compound having the following formula:




or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating chronic lymphocytic leukemia.

49. Use of a compound having the following formula:




or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating non-Hodgkin lymphoma.

50. Use of a compound having the following formula:




or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating diffuse large B-cell lymphoma.

51. Use of a compound having the following formula:




or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating mantle cell lymphoma.

52. Use of a compound having the following formula:




or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating adult T-cell lymphoma.

53. Use of a compound having the following formula:




or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating chronic lymphocytic leukemia.

54. Use of a compound having the following formula:




or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating non-Hodgkin lymphoma.

55. Use of a compound having the following formula:




or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating diffuse large B-cell lymphoma.

56. Use of a compound having the following formula:



or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating mantle cell lymphoma.

57. Use of a compound having the following formula:



or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating adult T-cell lymphoma.

58. The use of claim 36, wherein the leukemia is chronic lymphocytic leukemia.

59. The use of claim 36, wherein the lymphoma is non-Hodgkin lymphoma.

60. The use of claim 36, wherein the lymphoma is diffuse large B-cell lymphoma.

61. The use of claim 36, wherein the lymphoma is mantle cell lymphoma.

62. The use of claim 36, wherein the lymphoma is adult T-cell lymphoma.